Elanco’s acquisition of Bayer’s animal health business not opposed
The ACCC will not oppose Elanco’s acquisition of Bayer AG’s animal health business, after Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands.
The ACCC had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs.
Elanco will divest Avenge+ Fly, a sheep lice treatment, as well as Drontal, Profender and Droncit which treat gastro intestinal worms in cats and dogs. The future buyer or buyers of these brands will need to be approved by the ACCC.